Agfa submitted mdr report # 1225058-2010-00001 to the fda on 06/07/2010 for a site in the united states.A 14th occurrence is being reported for the same issue/same device: impax cv results mgmt administration tool (rmat).This is an internal discovery determined during the implementation of the associated problem correction plan, rmat verification, as reported in fda z-2112-10.
|
An agfa clinical analyst performed a retro-analysis and reported the findings to quality manager.Agfa's investigation into this occurrence of ramat customizations has revealed that this specific change had the potential to introduct clinical inaccuracies in pt reports.Specifically: the original sentence finding of "a left ventricular pseudoaneurysm of the septal wall is observed" was changed to " the echo findings suggest there is a pseudoaneurysm involving the apex of the left ventricle".In this issue, the original sentence describes the presence of a pseudoaneurysm of he septal wall.This was changed to indicate the presence of a pseudoaneurysm of the apex of the lv not the septal wall as intended.This is not the location intended for the reading physician and is clinically inaccurate.Potential impact: if the change was made after reports had been generated with the original sentence selected, those reports prior to the change display incorrect clinical data if viewed in rm or if used as a template for a repeat study on that pt.A soon as agfa is made aware of any affected reports to this specific findings, follow-up mdrs will be submitted for each associated study date and respective medical record number/s (mrn) identified.There has been no reported pt harm for this occurrence.A reportable correction is underway for this issue and has been reported to the fda via ref # z-2112-10.Agfa will follow the rmat post market verification work instructions to correct the sentence finding.Any further investigation for the site described in this report will be documented in the ongoing cfr part 806 reporting.
|